NCT00394446已完成1 期
Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Myrexis Inc.
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced or Metastatic Cancer
- •Measurable / Evaluable Disease
- •Karnofsky score greater than or equal to 70%
- •Adequate Hematology / Organ function
- •No Baseline peripheral or central neuropathy above grade 1
排除标准
- •Hypersensitivity to Cremophor EL
- •Pregnant or Lactating
- •Spinal Cord Compression
- •Pre-existing Dementia / Cognitive Disfunction
- •Require Neupogen or Neulasta to Maintain Neutrophil Count
- •Have Primary Brain Cancer
- •Have history of Ischemic Heart Disease
- •Have Diabetes
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 1 year
Pharmacokinetics
时间窗: 22 months
次要结局
- Antitumor Activity(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain MetastasesBrain NeoplasmsNCT00393965Myrexis Inc.18
终止
1 期
Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory CancerCancerNCT00387153Myriad Therapeutics, Inc.8
招募中
1 期
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT04768868Impact Therapeutics, Inc.350
已完成
1 期
Dose-Escalation Study of GSK2126458Solid TumoursNCT00972686GlaxoSmithKline79
已完成
1 期
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsAdvanced/Metastatic Solid TumorsNCT04501276Adagene Inc72